623 results on '"Grass, G."'
Search Results
2. Exploring the adsorptive potential of layered double hydroxides for chromium(VI) remediation
3. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
4. From Detection to Cure – Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer
5. Vorschlag für ein Verfahren zur Teilnahme an intensiv- und notfallmedizinischen Studien bei nichteinwilligungsfähigen Patient*innen (Kölner Modell)
6. Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience.
7. A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder
8. Brachytherapy and external beam radiation in the management of primary penile cancer – Game changer for organ preservation?
9. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
10. Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases
11. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma
12. Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
13. PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
14. Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer
15. Towards Data Driven RT Prescription: Integrating Genomics into RT Clinical Practice
16. Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer
17. Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence
18. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability
19. Impact of radiation therapy on perineal urethrostomy for penile cancer
20. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
21. Effectiveness and Safety of Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia in Men with Concurrent Localized Prostate Cancer
22. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC
23. BatchFLEX: feature-level equalization of X-batch.
24. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
25. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis
26. UTILIZING LOW-PASS WHOLE GENOME SEQUENCING OF URINARY-TUMOR DNA TO IDENTIFY MINIMAL RESIDUAL DISEASE PRIOR TO REPEAT TRANSURETHRAL RESECTION OF BLADDER TUMOR
27. IDENTIFYING THE DRIVER HISTOLOGY RESPONSIBLE FOR THE INFERIOR CLINICOPATHOLOGIC FEATURES ASSOCIATED WITH PLASMACYTOID BLADDER CANCER
28. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis
29. Current national proposals are off track to meet carbon dioxide removal needs
30. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management
31. The effect of germline DNA repair mutations on radiosensitivity in pancreatic ductal adenocarcinoma.
32. Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid Structures
33. Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer Patients
34. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose
35. Vorschlag für ein Verfahren zur Teilnahme an intensiv- und notfallmedizinischen Studien bei nichteinwilligungsfähigen Patient*innen (Kölner Modell)
36. Alterations in tumor immune microenvironment and progressive immune exhaustion with advancing penile squamous cell carcinoma using multiplex immunofluorescence and image analysis.
37. NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma.
38. The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma—A Systematic Review
39. Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy
40. The immune mechanisms of abscopal effect in radiation therapy
41. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation
42. Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage.
43. Abstract CT157: Combination of nivolumab with standard of care in the management of grade group 5 prostate cancer: Interim analysis of a phase II trial
44. Data from Hyaluronan, CD44, and Emmprin Regulate Lactate Efflux and Membrane Localization of Monocarboxylate Transporters in Human Breast Carcinoma Cells
45. Supplementary Figure Legend from Hyaluronan, CD44, and Emmprin Regulate Lactate Efflux and Membrane Localization of Monocarboxylate Transporters in Human Breast Carcinoma Cells
46. Supplementary Figure 1 from Hyaluronan, CD44, and Emmprin Regulate Lactate Efflux and Membrane Localization of Monocarboxylate Transporters in Human Breast Carcinoma Cells
47. DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components
48. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension
49. Additional file 5 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
50. Additional file 9 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.